Investing.com - Regeneron Pharma (NASDAQ:REGN) reported fourth quarter earnings that beat analysts' expectations on Wednesday and revenue that topped forecasts.
The firm reported earnings per share of $6.84 on revenue of $1.93B. Analysts polled by Investing.com anticipated EPS of $5.59 on revenue of $1.72B. That compared to EPS of $5.23 on revenue of $1.58B in the same period a year earlier. The company had reported EPS of $5.87 on revenue of $1.66B in the previous quarter.
Regeneron Pharma follows other major Healthcare sector earnings this month
On January 22, J&J reported fourth quarter EPS of $1.97 on revenue of $20.39B, compared to forecasts of EPS of $1.95 on revenue of $20.2B.
Pfizer earnings beat analyst's expectations on January 29, with fourth quarter EPS of $0.64 on revenue of $13.98B. Investing.com analysts expected EPS of $0.63 on revenue of $13.9B
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar